L&C Bio’s Human-Fat Injection Could Fix “Ozempic Face”: Will Gains Hold?
L&C Bio Co., Ltd. (290650.KQ) shares jumped almost 12% Thursday on plans for an Ozempic face repair comprised of donated human fats.
The KOSDAQ-listed inventory reached 64,600 gained intraday, up 11.76%, per Yahoo Finance information, extending a five-day acquire of roughly 24%. Investors welcomed the information as a recent development avenue past the agency’s present skincare line.
An Ozempic Side Effect Becomes a Business Plan
GLP-1 (glucagon-like peptide-1) medicine corresponding to Ozempic drive fast weight reduction. Some customers then develop a gaunt, hollowed look generally known as “Ozempic face,” and L&C Bio desires to deal with that hole instantly.
The market behind that downside is increasing quick. J.P. Morgan Research initiatives the U.S. affected person base for GLP-1 medicine will climb from 12.9 million in 2026 to 30.3 million by 2030, break up between kind 2 diabetes and weight problems sufferers. Each new weight problems affected person on an Ozempic-class drug is a possible candidate for facial quantity loss, and subsequently a possible buyer for L&C Bio.
The firm’s deliberate product, tentatively named MegaAdipoECM, converts donated human fats into an extracellular matrix scaffold. Patients’ personal fats cells then repopulate the handled space, restoring quantity with out artificial filler.
“We pioneered using donated human tissue in Ok-beauty pores and skin boosters.”
Lee Whan Chul, CEO, L&C Bio (SCMP)
The method differs from Re2O, L&C Bio’s flagship product, which makes use of donated pores and skin tissue for wrinkles moderately than quantity. Meanwhile, the brand new booster might additionally function an alternative choice to silicone breast implants, widening its potential market past Ozempic customers alone.
A Legal Shift Unlocks a Cheap Raw Material
South Korean legislation beforehand labeled donated fats as medical waste, which blocked industrial use totally. That modified in 2026, when regulators reclassified the tissue. However, a one-year grace interval means L&C Bio doesn’t anticipate a industrial launch earlier than late 2027.
The delay has not dampened investor enthusiasm. L&C Bio holds patents in South Korea, the United States, and China, the three markets it plans to focus on first. Therefore, L&C Bio already has authorized safety earlier than any product reaches cabinets. That safety turns a waste product right into a low-cost enter for a worldwide aesthetics enterprise constructed round Ozempic-era demand.
The rally additionally lands inside a rocky 2026 for Korean equities. Trading volumes cratered throughout a KOSDAQ crash this yr, and a chip stock selloff additionally rattled the KOSPI in July. Some merchants even confirmed indicators of capital fleeing to crypto throughout previous fairness swoons.
L&C Bio’s leap suggests a powerful biotech story can nonetheless lower by way of that volatility. The inventory now carries a market capitalization of 1.578 trillion gained, on quantity of 366,542 shares, near its common.
Yahoo Finance information additionally lists a one-year value goal of 99,000 gained, effectively above Thursday’s stage. However, the inventory’s 52-week vary of 29,100 to 125,000 gained exhibits simply how unstable shares have already been.
Whether L&C Bio turns patent safety into income by 2027 stays the open query for this Ozempic face repair.
The put up L&C Bio’s Human-Fat Injection Could Fix “Ozempic Face”: Will Gains Hold? appeared first on BeInCrypto.